The pharmaceutical landscape is undergoing a revolution with the emergence of novel glucagon-like peptide-1 (GLP-1) receptor agonists. These innovative drugs demonstrate are peptide injections dangerous immense potential in managing type 2 diabetes and, increasingly, are being explored for their therapeutic benefits in other conditions like obesity